Tan Li

Founder at SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

Net worth: 584 M $ as of 2024-04-29

60 year

100 connections

Health Technology

Consumer Services

Distribution Services

Profile

Tan Li founded Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Ms. Li is Executive Director & Deputy General Manager at this company and Executive Partner at Urumqi Jintiantu Equity Investment Partnership LP. Ms. Li is also on the board of Kymab Ltd., Shenzhen Techdow Pharmaceutical Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. and Kymab Group Ltd. She received an undergraduate degree from Sichuan University.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. CLASS A 32.72%	2023-06-29	408,041,280 ( 32.72% )	584 M $	2024-04-29

Tan Li active positions

Companies	Position	Start
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.	Founder	1998-04-20
Urumqi Jintiantu Equity Investment Partnership LP	Corporate Officer/Principal	2013-08-08
Shenzhen Techdow Pharmaceutical Co., Ltd.	Director/Board Member	-
Shenzhen Duopule Industrial Development Co., Ltd. Shenzhen Duopule Industrial Development Co., Ltd. Wholesale DistributorsDistribution Services Part of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. distributes biochemical products. The company is based in Shenzhen, China. Shenzhen Duopule Industrial Development Co. was acquired by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on May 31, 2017 for $414.58 million.	Director/Board Member	2014-01-12
Kymab Ltd. Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.	Director/Board Member	-
Kymab Group Ltd. Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.	Director/Board Member	2017-01-19

All active positions of Tan Li

Training of Tan Li

Sichuan University

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Tan Li's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.	Health Technology

Private companies	5
Urumqi Jintiantu Equity Investment Partnership LP
Kymab Ltd. Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.	Health Technology
Shenzhen Techdow Pharmaceutical Co., Ltd.
Shenzhen Duopule Industrial Development Co., Ltd. Shenzhen Duopule Industrial Development Co., Ltd. Wholesale DistributorsDistribution Services Part of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. distributes biochemical products. The company is based in Shenzhen, China. Shenzhen Duopule Industrial Development Co. was acquired by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on May 31, 2017 for $414.58 million.	Distribution Services
Kymab Group Ltd. Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.	Health Technology

See company connections